Upside-Trade-off Check
Interrogate every exciting benefit by finding the cost, risk, and dependency
- Difficulty
- Easy
- Time to result
- ~days to results
- Steps
- 6
- Confidence
- 91%
Bartlett states a general rule: when an intervention is presented as having tremendous upside, immediately ask what the trade-off is. Tatem then applies that question to peptides by identifying uncertainty about product identity and contamination, intervention-specific adverse effects, the possibility of losing gains after stopping, and the work that medication cannot perform. The framework converts a headline promise into a balanced decision. Define the claimed benefit, enumerate direct risks, include unknown evidence or manufacturing quality, test dependence by imagining withdrawal, and identify complementary behaviours still required. The output is not automatic rejection; it is a clearer net-benefit judgement made with appropriate professional input.
Origin
Extracted from The Diary of a CEO
Core principles
- 01Large benefits usually carry costs or constraints
- 02Unknowns are part of the trade-off
- 03Short-term gains can create long-term dependency
- 04A benefit is meaningful only relative to its downside
How to run it
- 1
Specify the upside
Translate the exciting promise into a concrete outcome, time horizon, and expected magnitude.
Pro tip Separate the speaker's claim from established evidence.
Watch out Vague promises make risks look smaller than they are.
- 2
Find the direct costs
List adverse effects, money, effort, monitoring, and opportunity costs that occur while using the intervention.
Pro tip Include low-frequency harms even when the average response sounds positive.
Watch out A targeted mechanism does not mean zero off-target effects.
- 3
Price the unknowns
Assess gaps in human evidence, long-term data, product identity, purity, and dosing confidence.
Pro tip Treat uncertainty as a risk category rather than as reassurance.
Watch out Absence of observed harm is not proof of safety.
- 4
Run the stop test
Ask what happens if the intervention is withdrawn and whether the benefit persists without it.
Pro tip Plan the maintenance or exit path before starting.
Watch out Removing an unchanged intervention can return the system toward its prior state.
- 5
Name the work it cannot do
Identify behaviours, skills, or treatments that remain necessary even if the intervention works.
Pro tip Pair the tool with the smallest set of essential supporting behaviours.
Watch out Do not mistake assistance for replacement.
- 6
Judge the net trade
Compare the measurable upside with direct costs, unknowns, dependency, and required support before deciding.
Pro tip Use an appropriately qualified adviser when the consequences are medical or otherwise high stakes.
Watch out A different patient or context may produce a different decision.
In the wild
The promised upside is faster recovery. The check then exposes uncertain vial contents, possible contamination, dosing uncertainty, limited human evidence, and no reliable clinical monitoring. Even if the biological mechanism is plausible, those manufacturing and evidence risks can dominate the expected benefit. Tatem's advice in the episode is not to buy research-use-only compounds.
→ The intervention is deferred until a legal, quality-controlled, supervised route is available.
A founder hears that a supplement sharply improves concentration. They define the desired outcome, check adverse effects and evidence quality, ask whether tolerance or rebound follows withdrawal, and identify sleep and workload changes the supplement cannot replace. The review may still support a monitored trial, but only after the full trade is visible.
→ A seductive promise becomes a bounded, evidence-aware decision.
Common mistakes
Counting only visible side effects
Evidence gaps, poor manufacturing controls, and dependence are also costs even when no immediate symptom appears.
Assuming assistance replaces effort
The episode repeatedly notes that medication does not perform resistance training, improve diet, or create durable habits by itself.
Planning the exit too late
Waiting until withdrawal to consider rebound leaves no maintenance strategy in place.
Is it for you?
Best for
Decisions involving medical, performance, financial, or lifestyle interventions with persuasive headline benefits.
Not ideal for
Time-critical emergencies where a qualified professional must act before a full comparison is possible.
From the transcript
“If you ever hear on a podcast or in any medium that something has tremendous upsides, the first question one should ask is what's the…”
“The biggest trade-off right now is you don't know if you're even getting what you're what you want”
“There are no real shortcuts. There are things that can help”
From the episode
The Peptide Expert: Big Pharma Are Hiding This Powerful Peptide From You! - Dr. Alex Tatem